Lipoprotein abnormalities in T2D and metabolic syndrome

The aggressive diagnosis and treatment of patients with type 2 diabetes, metabolic syndrome or insulin resistance, and atherogenic dyslipidemia has been advocated by the ADA, AHA, NCEP, and NLA. By diagnosing and aggressively treating patients at increased risk for cardiovascular disease, clinicians can reduce the burden these diseases place on patients and society (Journal of the American Academy of Physician Assistants)